What’s Propelling Axsome Therapeutics Inc (AXSM) to Increase So Much?

September 17, 2017 - By Richard Conner

The stock of Axsome Therapeutics Inc (NASDAQ:AXSM) is a huge mover today! The stock increased 4.21% or $0.2 on September 15, reaching $4.95. About 104,839 shares traded. Axsome Therapeutics Inc (NASDAQ:AXSM) has declined 59.08% since September 17, 2016 and is downtrending. It has underperformed by 75.78% the S&P500.
The move comes after 5 months positive chart setup for the $116.87 million company. It was reported on Sep, 17 by Barchart.com. We have $5.10 PT which if reached, will make NASDAQ:AXSM worth $3.51 million more.

Axsome Therapeutics Inc (NASDAQ:AXSM) Ratings Coverage

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, December 15 by Cantor Fitzgerald. The firm has “Buy” rating given on Monday, December 14 by Ladenburg Thalmann. The company was initiated on Monday, October 3 by Brean Capital.

More notable recent Axsome Therapeutics Inc (NASDAQ:AXSM) news were published by: Seekingalpha.com which released: “Axsome Therapeutics: An Undervalued Promising CNS Disease Company” on June 07, 2016, also Globenewswire.com with their article: “Axsome Therapeutics Reports Third Quarter 2016 Financial Results” published on November 14, 2016, Quotes.Wsj.com published: “Axsome Therapeutics Inc.” on November 06, 2015. More interesting news about Axsome Therapeutics Inc (NASDAQ:AXSM) were released by: Seekingalpha.com and their article: “Axsome Therapeutics Sweetens The Deal For Investors” published on August 29, 2017 as well as Seekingalpha.com‘s news article titled: “An Analysis Of Axsome Therapeutics’ Upcoming Catalysts” with publication date: May 25, 2017.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $116.87 million. The Firm is engaged in developing therapies for the management of central nervous system disorders, including pain. It currently has negative earnings. It operates in the business of developing novel therapies for the management of CNS disorders segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.